﻿$74 Billion Merger

$74 Billion Merger

In a federal class action, shareholders say directors are selling Celgene Corp. too cheaply through an unfair process to Bristol-Myers Squibb, for $50 a share plus a 1-for-1 share swap, a $74 billion merger.

WILMINGTON, Del. — In a federal class action, shareholders say directors are selling Celgene Corp. too cheaply through an unfair process to Bristol-Myers Squibb, for $50 a share plus a 1-for-1 share swap, a $74 billion merger. Bristol-Myers Squibb is not a party to the complaint.

Categories / Business, Health, Securities

Subscribe to our free newsletters

Our weekly newsletter Closing Arguments offers the latest about ongoing trials, major litigation and rulings in courthouses around the U.S. and the world, while the monthly Under the Lights dishes the legal dirt from Hollywood, sports, Big Tech and the arts.

﻿$74 Billion Merger

Subscribe to our free newsletters

Additional Reads

$74 Billion Merger